Clinical Trial Update: Personalized Therapy for Esophagogastric Cancer Using Thymidylate Synthase Genetic Markers [Phase 2]

View source ↗

Summary

Phase 2 trial of personalized therapy for esophagogastric cancer using thymidylate synthase genetic markers has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophageal Cancer
• Gastric Cancer

Snippet

Sponsor: Washington University School of Medicine | Conditions: Esophagogastric Cancer | Phase 2 | Status: WITHDRAWN